Italia markets close in 53 minutes

Gilead Sciences, Inc. (1GILD.MI)

Milan - Milan Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
64,21-0,19 (-0,30%)
In data: 09:21AM CEST. Mercato aperto.
Schermo intero
Chiusura precedente64,40
Aperto64,21
Denaro63,18 x N/D
Domanda63,44 x N/D
Min-Max giorno64,21 - 64,21
Intervallo di 52 settimane58,32 - 81,64
Volume50
Media Volume201
Capitalizzazione79,996B
Beta (mensile su 5 anni)0,22
Rapporto PE (ttm)194,58
EPS (ttm)0,33
Prossima data utili08 ago 2024
Rendimento e dividendo (futuro)2,88 (4,50%)
Data ex dividendo14 giu 2024
Stima target 1AN/D
  • GlobeNewswire

    Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032

    PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic

  • GlobeNewswire

    Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States

    LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care. Despite the availability of existing tr